NCT00986778

Entecavir Plus Adefovir in Lamivudine-Resistant Patients

A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

Combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in Chinese adults with lamivudine-resistant chronic hepatitis B infection

Conditions

• Hepatitis B, Chronic

Interventions

Type	Name	Description
DRUG	Lamivudine	Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
DRUG	Entecavir	Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
DRUG	Adefovir	Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response

Timeline

• Start date: 2009-12-01
• Primary completion: 2012-12-01
• Completion: 2014-06-01
• First posted: 2009-09-30
• Last updated: 2015-09-01